Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886800 | 0.86 | NOD1 (0.50) | SCN9AKCNH2SCN5AMAPK14MAPT | |
| SCHEMBL5886828 | 0.84 | NAMPT (0.49) | NAMPTROCK2MAPTTP53ADAMTS4 | |
| SCHEMBL5886740 | 0.82 | NOD1 (0.53) | MAPTTP53 | |
| SCHEMBL5886722 | 0.81 | RXRA (0.46) | SCN9AMAPTPTPN11ADAMTS4 | |
| SCHEMBL5887057 | 0.81 | DRD2 (0.41) | SCN9AMAPTADAMTS4 | |
| SCHEMBL5887072 | 0.80 | ALDH1A1 (0.40) | SCN9AMAPTADAMTS4 | |
| SCHEMBL5887156 | 0.79 | ADAMTS4 (0.43) | SCN9AADAMTS4 | |
| SCHEMBL5886750 | 0.79 | ADAMTS4 (0.45) | NAMPTROCK2MAPTTP53ADAMTS4 | |
| SCHEMBL5887343 | 0.79 | PRMT5 (0.43) | MAPTADAMTS4 | |
| SCHEMBL5886716 | 0.79 | SMN1; SMN2 (0.41) | MAPK14TP53KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | NAMPT 527/4885SCN9A 4214/4885KCNH2 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.